Abatacept Biosimilar, Endotoxin 0.05 EU/mg
Abatacept Biosimilar, Endotoxin 0.05 EU/mg. Orencia biosimilar CHO stable cell line is available for licensing to manufacture the abatacept biosimilar protein.The research grade abatacept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available.
- 产品参数
- 文献
- More Offers
| 货号 | C007P.05 |
|---|---|
| 产品名称 | Abatacept Biosimilar, Endotoxin 0.05 EU/mg |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | 悉得（Syd Labs） |
| 别称 | Orencia, CTLA-4 Fc Fusion Protein |
| 概述 | Recombinant protein composed of the extracellular domain of CTLA-4 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1). |
| 来源 | The abatacept biosimilar protein was produced in the Orencia biosimilar CHO stable cell line. |
| 特异性 | The abatacept biosimilar protein specifically binds to the human CD80 (B7-1) with more avidity than to CD86 (B7-2). |
| 应用 | Functional assays, and those assays for studying biological pathways affected by abatacept. |
| 抗体形式 | 0.2 uM filtered solution, pH 6.8 to 7.4, no stabilizers or preservatives. |
| 内毒素 | < 0.05 EU per 1 mg of the protein by the LAL method. |
| 纯度 | >95% by SDS-PAGE under reducing conditions and HPLC. |
| 运输 | The abatacept biosimilar protein is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| 稳定性与存储 | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| 注意事项 | Orencia biosimilar CHO stable cell line is available for licensing to manufacture the abatacept biosimilar protein.The research grade abatacept biosimilar protein is for research use only (RUO). Recombinant human IgG1 isotype controls and recombinant hIgG1 Fc proteins are available. |
| 线下下单 | 武汉多找找科技有限公司 电话: 18162581039 微信: duozhaozhao2024 Email: message@sydlabs.com或联系我们 |
描述
C007P.05: Abatacept Biosimilar, Endotoxin 0.05 EU/mg
Recombinant protein composed of the extracellular domain of CTLA-4 fused with the Fc region of human immunoglobulin gamma 1 (hIgG1).
Abatacept (trade name Orencia, Bristol-Myers-Squibb), a fusion protein of a Fc fragment (human IgG1 isotype) and the extracellular domain of CTLA-4, can be used to extend graft survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. Abatacept binds to CD80 (B7-1) with more avidity than to CD86 (B7-2). Abatacept inhibits the costimulation of T cells. Abatacept differs from belatacept (trade name Nulojix) by only 2 amino acids.
The CTLA-4 protein is important for T-cell costimulation and selectively blocks the process of T-cell activation.
Syd Labs also provides the following CTLA-4 Fc Fusion Protein biosimilar:
Belatacept Biosimilar
Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Please remember our product information: Abatacept Biosimilar, Endotoxin 0.05 EU/mg: C007P.05 Syd Labs